Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
43 studies found for:    "Thyroid cancer anaplastic"
Show Display Options
Rank Status Study
21 Completed Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
Condition: Head and Neck Cancer
Interventions: Biological: filgrastim;   Drug: fluorouracil;   Drug: hydroxyurea;   Drug: paclitaxel;   Procedure: conventional surgery;   Radiation: radiation therapy
22 Unknown  Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: pemetrexed + paclitaxel
23 Completed Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Condition: Thyroid Carcinoma
Intervention: Drug: Sorafenib (Nexavar,BAY43-9006)
24 Completed Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Conditions: Metastatic Differentiated Thyroid Cancer;   Metastatic Poorly Differentiated Thyroid Cancer;   Metastatic Anaplastic Thyroid Cancer;   Metastatic Medullary Thyroid Cancer
Intervention: Drug: sorafenib
25 Recruiting Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Conditions: Melanoma;   NSCLC;   Triple Negative Breast Cancer;   Anaplastic Thyroid Cancer;   Other Solid Tumors
Intervention: Biological: PDR001
26 Recruiting A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Conditions: Advanced Solid Tumors;   Non-Small Cell Lung Carcinoma (NSCLC);   Triple Negative Breast Cancer (TNBC);   Endometrial Cancer;   Anaplastic Thyroid Cancer
Interventions: Drug: FAZ053;   Drug: PDR001
27 Terminated Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
28 Completed Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
Conditions: Anaplastic Thyroid Cancer;   Insular Thyroid Cancer;   Metastatic Parathyroid Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Parathyroid Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Non-small Cell Lung Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Thryoid Gland Nonmedullary Carcinoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Intervention: Drug: gefitinib
29 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
30 Recruiting A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Conditions: Differentiated Thyroid Cancer (DTC);   Poorly Differentiated Thyroid Cancer
Intervention: Drug: Cabozantinib
31 Completed Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Condition: Head and Neck Cancer
Interventions: Drug: everolimus;   Other: laboratory biomarker analysis
32 Unknown  Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
Condition: Head and Neck Cancer
Intervention: Drug: everolimus
33 Completed Iodine I 131 in Treating Patients With Thyroid Cancer
Condition: Head and Neck Cancer
Interventions: Procedure: computed tomography;   Procedure: radionuclide imaging;   Procedure: single photon emission computed tomography;   Radiation: iodine I 131
34 Terminated Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Conditions: Melanoma;   Thyroid Cancer;   Colorectal Cancer;   Non-small Cell Lung Cancer;   Cholangiocarcinoma;   Histiocytosis;   Hairy Cell Leukemia
Intervention: Drug: PLX8394
35 Completed SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Condition: Head and Neck Cancer
Interventions: Drug: paclitaxel;   Drug: semaxanib
36 Recruiting Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Condition: Advanced Cancers
Interventions: Drug: Pembrolizumab;   Behavioral: Phone Call Follow-Up
37 Completed NGR-TNF in Treating Patients With Advanced Solid Tumors
Conditions: Colorectal Cancer;   Head and Neck Cancer;   Kidney Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: CNGRC peptide-TNF alpha conjugate
38 Completed Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Condition: Head and Neck Cancer
Intervention: Drug: gefitinib
39 Withdrawn S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Conditions: Breast Cancer;   Head and Neck Cancer;   Lung Cancer;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: docetaxel;   Drug: vandetanib;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacological study
40 Completed Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
Conditions: Colorectal Cancer;   Head and Neck Cancer;   Metastatic Cancer
Interventions: Drug: boronophenylalanine-fructose complex;   Drug: sodium borocaptate;   Procedure: conventional surgery

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-43) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.